|
Transmedics Group, Inc. (TMDX) DCF -Bewertung
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
TransMedics Group, Inc. (TMDX) Bundle
Unabhängig davon, ob Sie ein Investor oder Analyst sind, ist dieser (TMDX) DCF-Taschenrechner Ihre Anlaufstelle für eine genaue Bewertung. Mit realen Daten von Transmedics Group, Inc. können Sie Prognosen anpassen und die Effekte in Echtzeit beobachten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.6 | 30.3 | 93.5 | 241.6 | 441.5 | 773.5 | 1,355.2 | 2,374.2 | 4,159.4 | 7,287.0 |
| Revenue Growth, % | 0 | 18.03 | 208.83 | 158.53 | 82.74 | 75.19 | 75.19 | 75.19 | 75.19 | 75.19 |
| EBITDA | -23.2 | -38.5 | -29.0 | -7.6 | 69.9 | -322.7 | -565.4 | -990.5 | -1,735.3 | -3,040.1 |
| EBITDA, % | -90.31 | -127.18 | -30.99 | -3.15 | 15.84 | -41.72 | -41.72 | -41.72 | -41.72 | -41.72 |
| Depreciation | 1.6 | 2.6 | 4.2 | 8.2 | 19.8 | 42.1 | 73.8 | 129.4 | 226.6 | 397.0 |
| Depreciation, % | 6.15 | 8.74 | 4.49 | 3.38 | 4.47 | 5.45 | 5.45 | 5.45 | 5.45 | 5.45 |
| EBIT | -24.7 | -41.1 | -33.2 | -15.8 | 50.2 | -351.3 | -615.5 | -1,078.4 | -1,889.2 | -3,309.7 |
| EBIT, % | -96.46 | -135.93 | -35.48 | -6.53 | 11.37 | -45.42 | -45.42 | -45.42 | -45.42 | -45.42 |
| Total Cash | 125.6 | 92.5 | 201.2 | 394.8 | 336.7 | 736.8 | 1,290.8 | 2,261.4 | 3,961.8 | 6,940.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 6.9 | 5.9 | 27.6 | 63.6 | 97.7 | 192.4 | 337.1 | 590.5 | 1,034.6 | 1,812.5 |
| Account Receivables, % | 26.77 | 19.61 | 29.54 | 26.31 | 22.13 | 24.87 | 24.87 | 24.87 | 24.87 | 24.87 |
| Inventories | 11.9 | 14.9 | 20.6 | 44.2 | 46.6 | 226.7 | 397.2 | 695.9 | 1,219.1 | 2,135.8 |
| Inventories, % | 46.55 | 49.1 | 22.05 | 18.31 | 10.54 | 29.31 | 29.31 | 29.31 | 29.31 | 29.31 |
| Accounts Payable | 1.2 | 6.7 | 3.3 | 12.7 | 10.3 | 58.6 | 102.6 | 179.7 | 314.9 | 551.6 |
| Accounts Payable, % | 4.7 | 21.98 | 3.57 | 5.26 | 2.33 | 7.57 | 7.57 | 7.57 | 7.57 | 7.57 |
| Capital Expenditure | -.5 | -3.5 | -11.9 | -179.1 | .0 | -155.1 | -271.7 | -476.0 | -834.0 | -1,461.0 |
| Capital Expenditure, % | -1.77 | -11.63 | -12.74 | -74.11 | 0 | -20.05 | -20.05 | -20.05 | -20.05 | -20.05 |
| Tax Rate, % | 0.88317 | 0.88317 | 0.88317 | 0.88317 | 0.88317 | 0.88317 | 0.88317 | 0.88317 | 0.88317 | 0.88317 |
| EBITAT | -24.8 | -41.2 | -33.2 | -14.8 | 49.7 | -346.4 | -606.9 | -1,063.2 | -1,862.6 | -3,263.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -41.2 | -38.6 | -71.7 | -235.9 | 30.6 | -685.9 | -1,075.9 | -1,884.8 | -3,302.1 | -5,785.0 |
| WACC, % | 12.54 | 12.54 | 12.54 | 12.5 | 12.53 | 12.53 | 12.53 | 12.53 | 12.53 | 12.53 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -8,047.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -5,901 | |||||||||
| Terminal Value | -56,045 | |||||||||
| Present Terminal Value | -31,062 | |||||||||
| Enterprise Value | -39,109 | |||||||||
| Net Debt | 122 | |||||||||
| Equity Value | -39,232 | |||||||||
| Diluted Shares Outstanding, MM | 35 | |||||||||
| Equity Value Per Share | -1,114.00 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: TransMedics Group, Inc.'s (TMDX) financial data pre-filled to enhance your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A sleek Excel model tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for assessing projections, validating strategies, and optimizing your time.
Key Features
- Real-Life TMDX Data: Pre-filled with TransMedics Group’s historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
- User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.
How It Works
- 1. Access the Model: Download and open the Excel file containing TransMedics Group, Inc. (TMDX) preloaded data.
- 2. Adjust Key Inputs: Modify essential parameters such as growth projections, WACC, and capital expenditures.
- 3. Analyze Results Instantly: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Different Scenarios: Evaluate various forecasts to assess different valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation insights to enhance your decision-making process.
Why Choose This Calculator?
- Accurate Data: Up-to-date TransMedics Group financials provide trustworthy valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Built-in calculations save you from starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants focused on (TMDX).
- User-Friendly: Easy-to-navigate design and clear instructions make it accessible for everyone.
Who Should Use This Product?
- Investors: Evaluate TransMedics Group, Inc.'s (TMDX) market position before making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and assess financial forecasts for TMDX.
- Startup Founders: Understand the valuation strategies employed by innovative companies like TransMedics Group, Inc. (TMDX).
- Consultants: Provide detailed valuation insights and reports for clients in the healthcare sector.
- Students and Educators: Utilize real-life case studies to explore and teach valuation principles related to TMDX.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled TransMedics Group, Inc. (TMDX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models illustrating intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for TransMedics Group, Inc. (TMDX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to simplify result analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.